Prospects and progress of antibody-drug conjugates in solid tumor therapies

Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma

(2016) Bishoy Faltas et al.   Clinical Genitourinary Cancer

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

(2015) Thomas M. Cardillo et al.   BIOCONJUGATE CHEMISTRY

Mammalian Bcnt/Cfdp1, a potential epigenetic factor characterized by an acidic stretch in the disordered N-terminal and Ser250 phosphorylation in the conserved C-terminal regions

(2015) S. Iwashita et al.   BIOSCIENCE REPORTS

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

(2015) A. N. Starodub et al.   CLINICAL CANCER RESEARCH

Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)

(2015) R. M. Sharkey et al.   CLINICAL CANCER RESEARCH

An emerging playbook for antibody–drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety

(2015) Penelope M Drake et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin’s lymphomas

(2015) Maro Ohanian et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers.

(2015) Alexander Starodub et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Chemotherapy for Locally Advanced Rectal Cancer: Is It a Given?

(2015) Theodore S. Hong et al.   JOURNAL OF CLINICAL ONCOLOGY

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

(2015) Matthew J. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer

(2015) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates

(2015) Yuqin Yao et al.   JOURNAL OF CONTROLLED RELEASE

IMGN853, a Folate Receptor-  (FR )-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR -Expressing Tumors

(2015) O. Ab et al.   MOLECULAR CANCER THERAPEUTICS

Antibody Conjugates with Unnatural Amino Acids

(2015) Trevor J. Hallam et al.   MOLECULAR PHARMACEUTICS

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

(2015) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade

(2015) Philipp Müller et al.   Science Translational Medicine

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

(2015) Laura R. Saunders et al.   Science Translational Medicine

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

(2015) David M. Goldenberg et al.   Oncotarget

A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design

(2015) Christina Vasalou et al.   PLoS One

Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy

(2014) Ravi V. J. Chari et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

(2014) L. Amiri-Kordestani et al.   CLINICAL CANCER RESEARCH

Antibody drug conjugates

(2014) Beverly A. Teicher   CURRENT OPINION IN ONCOLOGY

Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma

(2014) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines

(2014) Charlene M. Dawidczyk et al.   JOURNAL OF CONTROLLED RELEASE

Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

(2014) John M. Lambert et al.   JOURNAL OF MEDICINAL CHEMISTRY

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

(2014) Robert K Hills et al.   LANCET ONCOLOGY

Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies

(2014) Antoine Deslandes   mAbs

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

(2014) S. Golfier et al.   MOLECULAR CANCER THERAPEUTICS

Improving the Therapeutic Index in Cancer Therapy by Using Antibody–Drug Conjugates Designed with a Moderately Cytotoxic Drug

(2014) Serengulam V. Govindan et al.   MOLECULAR PHARMACEUTICS

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

(2014) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

Methods to Make Homogenous Antibody Drug Conjugates

(2014) Toni Kline et al.   PHARMACEUTICAL RESEARCH

The Next Generation of Antibody Drug Conjugates

(2014) Fiona Mack et al.   SEMINARS IN ONCOLOGY

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

(2013) Scott C. Jeffrey et al.   BIOCONJUGATE CHEMISTRY

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

(2013) Hagop Kantarjian et al.   CANCER

An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors

(2013) E. C. W. Breij et al.   CANCER RESEARCH

Site-specific antibody drug conjugates for cancer therapy

(2013) Siler Panowski et al.   mAbs

Methods for site-specific drug conjugation to antibodies

(2013) Christopher R Behrens et al.   mAbs

Milatuzumab-SN-38 Conjugates for the Treatment of CD74+ Cancers

(2013) S. V. Govindan et al.   MOLECULAR CANCER THERAPEUTICS

Antibody-Drug Conjugates in Cancer Therapy

(2012) Eric L. Sievers et al.   Annual Review of Medicine

Brentuximab Vedotin

(2012) C. Deng et al.   CLINICAL CANCER RESEARCH

Designing immunoconjugates for cancer therapy

(2012) Serengulam V Govindan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

(2012) Peter D Senter et al.   NATURE BIOTECHNOLOGY

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

(2011) T. M. Cardillo et al.   CLINICAL CANCER RESEARCH

CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates

(2009) S. V. Govindan et al.   CLINICAL CANCER RESEARCH

A History of Cancer Chemotherapy

(2008) Vincent T. DeVita et al.   CANCER RESEARCH

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

(2007) Ravi V. J. Chari   ACCOUNTS OF CHEMICAL RESEARCH